July 29, 2020
- Solaris Admin
- Jul 28, 2020
- 1 min read
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Twice-A-Day) in 30 g and 60 g tubes a generic version of reference listed drug CLEOCIN T® (Clindamycin Phosphate) 1% Topical Gel.. For more updates, please feel free to email us info@solaris-pharma.com
Comments